Tom Frohlich - 28 Apr 2025 Form 3 Insider Report for Jade Biosciences, Inc. (JBIO)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Balta, as attorney-in-fact for Tom Frohlich
Issuer symbol
JBIO
Transactions as of
28 Apr 2025
Net transactions value
$0
Form type
3
Filing time
01 May 2025, 17:21:25 UTC
Previous filing
11 Aug 2023
Next filing
19 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JBIO Stock Option (Right to Buy) 28 Apr 2025 Common Stock 931,131 $1.53 Direct F1
holding JBIO Stock Option (Right to Buy) 28 Apr 2025 Common Stock 1,060,732 $6.03 Direct F2
holding JBIO Stock Option (Right to Buy) 28 Apr 2025 Common Stock 779,934 $6.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 931,131 shares of the Issuer's common stock, one quarter of which will vest on October 3, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F2 This option represents a right to purchase 1,060,732 shares of the Issuer's common stock, which vests in 48 equal monthly installments through January 29, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F3 This option represents a right to purchase 779,934 shares of the Issuer's common stock, one quarter of which will vest on January 29, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney